What makes Ex Vivo screening superior to In Vitro cell-based panning?

Ex Vivo screening preserves the tissue's 3D architecture and the natural extracellular matrix, which are often lost in 2D cell cultures. This leads to the discovery of ligands that are more likely to perform effectively in a living organism.

Which phage system is best for Ex Vivo Phage Library Screening?

It depends on the target. M13 is excellent for peptides and ScFv, while T7 is often preferred for its robustness and ability to display larger, more complex proteins or when rapid lytic cycles are needed.

Can Creative Biolabs perform screening on human clinical samples?

Yes, we can perform customized ex vivo phage screening on patient-derived biopsies or surgical specimens, provided all ethical and regulatory requirements are met.

How do you ensure the tissue remains viable during the screening?

We use specialized perfusion systems and physiological buffers that mimic the body's internal environment, ensuring the tissue remains metabolically active and the surface receptors remain functional.

Is NGS mandatory for your Ex Vivo screening service?

While not mandatory, we highly recommend NGS. It provides a much deeper analysis of the library's evolution and can identify potent candidates that traditional colony-picking might miss.

Can you identify ligands that internalize into the cells?

Yes, our platform includes specialized elution protocols designed to recover phages that have been internalized via endocytosis, which is crucial for developing antibody-drug conjugates (ADCs).

How do you handle non-specific binding to the vasculature?

We use a sophisticated "pre-clearing" or subtractive panning step against non-target tissues or endothelial cells to "mask" or remove common binders, focusing the library on target-specific motifs.

What deliverables will I receive at the end of the project?

You will receive a comprehensive report including detailed experimental report, all sequencing data (NGS or Sanger), motif analysis, and the physical clones or synthesized peptides of the top candidates.

Precision Ex Vivo Phage Library Screening Services

Background Platform Workflow Application Advantage Related Service FAQ Online Inquiry

In the intricate landscape of drug discovery and molecular targeting, the transition from in vitro cell cultures to in vivo animal models often presents a "valley of death" where promising candidates fail due to the loss of physiological relevance or excessive biological complexity. Creative Biolabs offers a sophisticated Ex Vivo Phage Library Screening service, providing a robust bridge that maintains the architectural integrity of organs while offering the controllability of a laboratory environment. Our ex vivo phage screening platform leverages the power of bacteriophage display to identify high-affinity ligands (peptides, antibodies, or scaffolds) that bind to specific cell types within their native tissue context. Unlike standard cell-based panning, our ex vivo phage display approach preserves the extracellular matrix (ECM), cell-cell interactions, and the spatiotemporal distribution of receptors, ensuring that the identified hits are highly translatable to clinical applications.

Discuss Your Project Today

Why Choose Ex Vivo Phage Library Screening?

The biological fidelity of ex vivo phage library selection offers unparalleled advantages:

Maintained Tissue Architecture: Organs or tissue biopsies are kept viable, preserving the 3D microenvironment.
Reduced Ethical Constraints: Maximizes data yield from minimal animal usage compared to full-scale in vivo studies.
High Specificity: Effectively filters out non-specific binders by using competitive "subtractive" panning against non-target tissues.
Accelerated Kinetics: Rapidly identify homing peptides or internalizing antibodies with superior pharmacokinetics.

Table 1. Comparison of Screening Modalities

Feature	In Vitro (Cell Culture)	Ex Vivo (Tissue/Organ)	In Vivo (Animal)
Physiological Relevance	Low	High	Very High
Complexity Control	Easy	Moderate	Difficult
Tissue Microenvironment	Absent	Preserved	Fully Integrated
Bioavailability Insight	None	Partial	High
Cost-Efficiency	High	High	Low

Our Advanced Ex Vivo Phage Screening Platform

Creative Biolabs has pioneered a customized ex vivo phage screening workflow that integrates cutting-edge micro-perfusion systems and AI-driven bioinformatics. Our platform is compatible with various phage systems, including M13, T7, and T4, tailored to the specific requirements of the project.

High-Diversity Phage Libraries

We maintain a vast repository of Ex Vivo Phage Libraries, including:

Random Peptide Libraries: Linear and cyclic (7-mer, 12-mer, 15-mer).
Antibody Libraries: ScFv, Fab, and V_HH libraries with diversities up to 10¹².
Focused Libraries: Tailored for specific protein families or post-translational modifications.

Tissue Viability Maintenance

The success of ex vivo phage library screening hinges on the health of the tissue. We utilize oxygenated physiological buffers and temperature-controlled perfusion chambers to ensure the proteomic landscape of the tissue remains unchanged during the incubation period.

Precision Biopanning Strategies

Our experts employ a multi-step selection process:

Pre-adsorption: Removing phages that bind to common endothelial markers or plastic surfaces.
Target Incubation: Controlled exposure of the phage library to the target organ (e.g., brain, liver, lung, or tumor biopsy).
Stringent Washing: Utilizing customized flow rates to remove weak and non-specific binders.
Elution and Amplification: Optimized recovery of internalized or high-affinity phages.

The Technical Workflow: A Step-by-Step Excellence

Tissue Sourcing & Preparation: Freshly harvested organs or patient-derived xenograft (PDX) tissues are prepared under aseptic conditions.
Library Customization: Selection of the optimal phage backbone based on the target (e.g., T7 for large protein displays or M13 for small peptides).
The Ex Vivo Challenge: The Ex Vivo Phage Library is introduced via perfusion or immersion. We simulate blood flow dynamics to identify ligands capable of navigating the vascular endothelium.
Next-Generation Sequencing (NGS) Integration: Unlike traditional plaque counting, we utilize NGS to track the enrichment of thousands of clones simultaneously, identifying rare but highly potent binders that might be lost in manual screening.
Bioinformatics & Motif Analysis: Deep learning algorithms are used to identify consensus sequences and structural motifs, predicting binding pockets and potential cross-reactivity.

Table 2. Key Technical Parameters of our Service

Parameter	Specification
Phage Systems	M13, T7, T4, λ phage
Library Diversity	10⁸ to 10¹² individual clones
Tissue Types	Biopsy, Whole Organ, Sliced Tissue (Vibratome)
Analysis Method	NGS, ELISA, Sanger Sequencing, LC-MS/MS
Validation Capability	Immunohistochemistry (IHC), SPR/BLI, In Vivo Imaging

Fig. 1 Workflow of Ex vivo Phage Display Screening. (Creative Biolabs Original) Fig. 1 Procedure for ex vivo phage display selection.

Key Applications of Ex Vivo Phage Display

Our customized ex vivo phage screening services have been instrumental in several high-impact research areas:

Blood-Brain Barrier (BBB) Penetration: Identifying shuttles for CNS drug delivery using ex vivo brain perfusion models.
Tumor Microenvironment Targeting: Selection of ligands that penetrate deep into the necrotic core of solid tumors.
Organ-Specific Homing: Developing targeted imaging agents for the heart, kidneys, or specialized lymphoid tissues.
Cross-Species Translation: Comparing binding profiles between murine, porcine, and human tissues to predict clinical success.

Why Creative Biolabs Stands Out

With over two decades of experience, Creative Biolabs is more than a service provider; we are your scientific partner. Our Ex Vivo Phage Library Screening service is backed by:

Expert Scientists: Ph.D. level project managers with extensive experience in phage biology and pharmacology.
State-of-the-Art Facilities: Cutting-edge labs equipped for complex organ perfusion and advanced molecular analysis.
Global Reach: Serving the top 50 pharmaceutical companies and leading academic institutions worldwide.
Data Integrity: Rigorous quality control and comprehensive reports that are ready for IND (Investigational New Drug) filings.

Explore Our Comprehensive Services

Learn more about other Phage Display Library Screening Services:

Ready to elevate your drug discovery program with our Ex Vivo Phage Library Screening? Our experts are available to discuss your specific project requirements and design a customized ex vivo phage screening strategy that meets your goals.

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQs)

Q: What makes Ex Vivo screening superior to In Vitro cell-based panning?
A: Ex Vivo screening preserves the tissue's 3D architecture and the natural extracellular matrix, which are often lost in 2D cell cultures. This leads to the discovery of ligands that are more likely to perform effectively in a living organism.
Q: Which phage system is best for Ex Vivo Phage Library Screening?
A: It depends on the target. M13 is excellent for peptides and ScFv, while T7 is often preferred for its robustness and ability to display larger, more complex proteins or when rapid lytic cycles are needed.
Q: Can Creative Biolabs perform screening on human clinical samples?
A: Yes, we can perform customized ex vivo phage screening on patient-derived biopsies or surgical specimens, provided all ethical and regulatory requirements are met.
Q: How do you ensure the tissue remains viable during the screening?
A: We use specialized perfusion systems and physiological buffers that mimic the body's internal environment, ensuring the tissue remains metabolically active and the surface receptors remain functional.
Q: Is NGS mandatory for your Ex Vivo screening service?
A: While not mandatory, we highly recommend NGS. It provides a much deeper analysis of the library's evolution and can identify potent candidates that traditional colony-picking might miss.
Q: Can you identify ligands that internalize into the cells?
A: Yes, our platform includes specialized elution protocols designed to recover phages that have been internalized via endocytosis, which is crucial for developing antibody-drug conjugates (ADCs).
Q: How do you handle non-specific binding to the vasculature?
A: We use a sophisticated "pre-clearing" or subtractive panning step against non-target tissues or endothelial cells to "mask" or remove common binders, focusing the library on target-specific motifs.
Q: What deliverables will I receive at the end of the project?
A: You will receive a comprehensive report including detailed experimental report, all sequencing data (NGS or Sanger), motif analysis, and the physical clones or synthesized peptides of the top candidates.

Reference

Saw, Phei Er, and Er-Wei Song. "Phage display screening of therapeutic peptide for cancer targeting and therapy." Protein & cell 10.11 (2019): 787-807. https://doi.org/10.1007/s13238-019-0639-7

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.